Market revenue in 2023 | USD 12.8 million |
Market revenue in 2030 | USD 20.8 million |
Growth rate | 7.3% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.16% in 2023. Horizon Databook has segmented the South Korea cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
The presence of key pharmaceutical companies and initiatives undertaken by them such as increasing focus on R&D and collaborations with local players to expand their market presence & strengthen their contract manufacturing capabilities in South Korea are contributing to the market growth.
For instance, Cyrus Therapeutics continuously focuses on developing small molecules that target immunosuppression in cancers. These molecules can be used as a monotherapy or in conjunction with other cancer medicines to increase the effectiveness of those therapies.
Moreover, the organization is using synthetic lethality to identify potential therapeutic targets, especially for individuals with BRCA1/2 mutations. When a mutation affects two genes, as opposed to simply one, the result is synthetic lethality, which results in cell death. As a result, treating some cancers may include locating the dormant gene in cancer cells and focusing on the other gene in the pair. These factors promote market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into South Korea cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account